CATX
Perspective Therapeutics, Inc.
There isn't enough reported data to score CATX yet.
CATX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
CATX's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
CATX PE Valuation
CATX has no meaningful PE right now: it lost money over the past year.
CATX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect CATX's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
CATX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.25 | +$0.46 |
| Q2 2026 | -$1.33 | +$0.24 |
| Q1 2026 | -$1.40 | +$0.06 |
| Q4 2025 | -$1.40 | +$0.01 |
| Q3 2025 | -$1.71 | -$0.94 |
| Q2 2025 | -$1.57 | -$0.61 |
| Q1 2025 | -$1.46 | -$0.28 |
| Q4 2024 | -$1.41 | -$0.43 |
CATX is still losing money, but less than at its worst: $1.25 per share over the past year, against $1.71 at its worst in late 2025.
CATX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2023 | $2.2M | +27% |
| Q2 2023 | $2.1M | -17% |
| Q1 2023 | $2.1M | -29% |
| Q4 2022 | $1.8M | -35% |
| Q3 2022 | $1.7M | -33% |
| Q2 2022 | $2.5M | -7.6% |
| Q1 2022 | $2.9M | +12% |
| Q4 2021 | $2.8M | +19% |
CATX's revenue has slid since its 2022 peak: −$5M last quarter, down 386% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2023 | -482% | -237 points |
| Q2 2023 | -545% | -461 points |
| Q1 2023 | -544% | -497 points |
| Q4 2022 | -175% | -117 points |
| Q3 2022 | -245% | -156 points |
| Q2 2022 | -84% | -44 points |
| Q1 2022 | -47% | -18 points |
| Q4 2021 | -58% | -21 points |
CATX's operating margin was −482% last quarter, down 237 points from the same quarter a year ago.
CATX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$35.9M | -$17.6M |
| Q2 2026 | -$34.8M | -$13.9M |
| Q1 2026 | -$38.3M | -$12.1M |
| Q4 2025 | -$29.7M | +$11.5M |
| Q3 2025 | -$18.3M | +$8.1M |
| Q2 2025 | -$21M | -$11.1M |
| Q1 2025 | -$26.2M | -649% |
| Q4 2024 | -$41.2M | -$32.1M |
CATX has burned cash in almost every quarter: −$139M over the past year, against −$107M the year before.
CATX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +97K shares |
| 1 year | +63% | +46.5M shares |
| 3 years | +331% | +92.7M shares |
| 5 years | +885% | +108M shares |
| Available history | +1692% | +114M shares |
CATX has 121M diluted shares, up 63% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q4 2022 | — |
CATX Net Leverage
CATX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CATX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.9 | Oversold |
| Stochastic | 2.7 | Oversold |
CATX's weekly RSI is 24 (oversold) and its Stochastic is 3 (oversold).
CATX PE vs Healthcare Sector
CATX has no meaningful PE right now: it lost money over the past year.
CATX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.82 | 54% below |
| 20 week MA | $2.57 | 67% below |
| 50 week MA | $3.29 | 74% below |
| 100 week MA | $3.19 | 74% below |
| 200 week MA | $5.58 | 85% below |
CATX is in a downtrend: it's below all five of its weekly moving averages, and 85% below its 200-week average.
CATX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.12 | $4.70 | -23% |
| 2021 | $4.70 | $4.06 | -14% |
| 2022 | $4.06 | $2.90 | -29% |
| 2023 | $2.90 | $4.02 | +39% |
| 2024 | $4.02 | $3.19 | -21% |
| 2025 | $3.19 | $2.88 | -9.7% |
| 2026 YTD | $2.88 | $0.84 | -71% |
CATX has finished lower in five of the last six years. It's down 71% so far in 2026.